Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a blank-check shell, not an operating business. It reports no revenue in any filed period: in fiscal Q2 2026, the quarter ended 2026-06-30, net income was $1.7M; in fiscal Q1 2026, the quarter ended 2026-03-31, net income was $2.0M; in fiscal Q3 2025, the quarter ended 2025-09-30, net income was $2.2M; in fiscal Q2 2025, the quarter ended 2025-06-30, net income was $2.3M; and in FY2025, the period ended 2025-12-31, net income was $5.9M. Those positive figures did not come from sales—there were none reported—so I cannot underwrite an operating franchise or a moat. Indeed, the company states it has no significant operations and intends to effect a merger or similar combination. Financial health is hard to judge. Trailing free cash flow is -$517,145, a -0.2% FCF yield, and ROCE is -1.46%. The FairStock Piotroski F-Score is 1/9, signaling weak accounting and operating signals, though the FairStock Altman Z-Score of 17.22 suggests low near-term balance-sheet distress by that formula. There is no dividend, no meaningful revenue growth, and profit growth is calculated at -24.54%. Valuation is the rub. At the $10.86 close on 2026-10-13, market cap is $263.6M and the FairStock P/E is 60.33 on EPS of $0.18. The Graham Number is $4.79, implying a Margin of Safety of -126.72%—price is far above that conservative estimate. The 52-week range is $10.29-$10.89, so the shares sit near their high. FairStock Score 16/100 and Lynch category none, because there is only one year of filed results and three are needed, reinforce a speculative, unproven profile. Until a real business is acquired and financials become auditable over time, this is a promise, not a value investment.

In plain English: This company does not run an operating business yet; it is a shell that plans to merge with another company. It reported no revenue in the periods given, and its cash flow is negative. At $10.86, the price looks expensive relative to the small earnings and conservative value estimates in the data.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer